You are here

  • Home
  • Archive
  • Volume 19, Issue 9
  • Lack in Efficacy for Imatinib Mesylate as Second-Line Treatment of Recurrent or Metastatic Cervical Cancer Expressing Platelet-Derived Growth Factor Receptor α

Article metrics

Article menu
Download PDFPDF
Cervical Cancer
Lack in Efficacy for Imatinib Mesylate as Second-Line Treatment of Recurrent or Metastatic Cervical Cancer Expressing Platelet-Derived Growth Factor Receptor α

 

Online download statistics by month:

Online download statistics by month: March 2019 to April 2024

AbstractFullPdf
Mar 20191400
Apr 20191600
May 20193100
Jun 20192301
Jul 20192600
Aug 20192100
Sep 20191701
Oct 20191000
Nov 2019603
Dec 20191400
Jan 20201600
Feb 20202700
Mar 20203400
Apr 20201103
May 20202100
Jun 20204500
Jul 20201000
Aug 20201400
Sep 20201400
Oct 20201300
Nov 20201700
Dec 20201200
Jan 20212000
Feb 2021600
Mar 20211800
Apr 2021800
May 2021300
Jun 2021300
Jul 2021001
Sep 2021101
Oct 20211000
Nov 2021600
Dec 20212200
Jan 20223300
Feb 20221300
Mar 20222200
Apr 20221200
May 20223900
Jun 20224400
Jul 20222601
Aug 20224801
Sep 20224200
Oct 20223800
Nov 20221500
Dec 20223000
Jan 20232000
Feb 20239200
Mar 20231400
Apr 20231300
May 20232000
Jun 20231600
Jul 2023600
Aug 20232000
Sep 20231600
Oct 20231200
Nov 20231300
Dec 20231600
Jan 20241000
Feb 20241300
Mar 20241200
Apr 20241100
Total1175012